# OnCo record nct07821684 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07821684/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07821684", "NCT07821684" ;
  schema:name "A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanc"@en ;
  schema:description "A phase 3 trial of telisotuzumab adizutecan, docetaxel and ramucirumab in lung cancer, run by AbbVie, not yet recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07821684/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07821684> ;
  onco:status "planned" ;
  onco:tag "ctgov-ingest", "lung-deep-dive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/egfr-mutant-nsclc/>, <https://onco.cc/cancers/met-altered-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:drugs <https://onco.cc/drugs/telisotuzumab-adizutecan/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/ramucirumab/> ;
  onco:companies <https://onco.cc/companies/abbvie/> .